Clinical trial NCT03903926: Efficacy Trial of a Commercial EV71 Vaccine
Official title: Phase Ⅳ Clinical Trial, to Evaluate the Efficacy of the Enterovirus 71 (EV71) Inactivated Vaccine and Its Correlation With EV71 Antibody Level
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hand, Foot and Mouth Disease
Keywords: EV71 vaccine; Efficacy; Seroprotective correlates
Lead sponsor: Sinovac Biotech Co., Ltd
Sponsor class: INDUSTRY
First posted: 2019-04-04
Enrollment: 15500
Sex: ALL
Minimum age (years): 6
Maximum age (years): 71
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this post-marketing study is to evaluate the efficacy, immunogenicity, and safety of the EV71 vaccine post marketing, and explore the protective levels of various enterovirus neutralizing antibodies

Detailed description: This study is a post-marketing aims to evaluate the efficacy, immunogenicity, and safety of the EV71 vaccine, and explore the protective levels of various enterovirus neutralizing antibodies. This study includes the following three sections: (1) efficacy study of EV71 vaccine based on enhanced cases monitoring, using prospective cohort study design (2) study on correlation between EV71 vaccine protection and EV71 antibody levels, using case-control study design (3) pathogenic spectrum and sero-epidemiological investigation of hand, foot and mouth disease (HFMD) in children. 15500 volunteers aged 6-71 months are expected to participate in this study, among which 5000 volunteers aged 6-35 months will receive two doses EV71 vaccine manufactured by Sinovac Biotech Co., Ltd, and constitute the experimental cohort. 10000 unvaccinated volunteers aged 6-35 months will constitute the the control cohort. The efficacy evaluation will be conducted based on the abovementioned two cohort. Enhanced HFMD surveillance system will be established to report the HFMD cases in the abovementioned 2 cohorts, as well as another cohort consisting of 500 volunteers aged 36-71 months. The case surveillance period of this study is one year. Laboratory tests will be conducted for case confirmation.

Eligibility criteria: Inclusion Criteria:

* Volunteers aged 6-71 months;
* Guardians of the participants voluntarily to vaccinate the participants with EV71 vaccine at their own expense;
* Guardians of the participants should be capable of understanding the written consent form, and such form should be signed prior to enrollment;
* Complying with the requirement of the study protocol;

Exclusion Criteria:

* History of HFMD prior to the study entry;
* Prior vaccination with EV71 vaccine;
* History of allergy to any vaccine, or any ingredient, excipients and Gentamycin Sulfate of the vaccine, or serious adverse reaction(s) to vaccination, such as urticaria, dyspnea, angioneurotic edema, abdominal pain, etc. (only for 6-35 months old subjects of the vaccinated group) ;
* Congenital malformation, developmental disorders, genetic defects, or severe malnutrition (only for 6-35 months old subjects of the vaccinated group);
* Severe/uncontrollable nervous system disease (epilepsy, seizures or convulsions) or mental illness (only for 6-35 months old subjects of the vaccinated group);
* Autoimmune disease or immunodeficiency/immunosuppressive (only for 6-35 months old subjects of the vaccinated group) ;
* History of asthma, angioedema, diabetes or malignancy (only for 6-35 months old subjects of the vaccinated group);
* Acute disease or acute stage of chronic disease within 7 days prior to study entry (only for 6-35 months old subjects of the vaccinated group);
* Axillary temperature \> 37.0 Celsius (only for 6-35 months old subjects of the vaccinated group)；
* Any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators.

Primary outcomes:
measure: The efficacy of two doses EV71 vaccine in the 6-35 months old subjects
timeFrame: During the case monitoring period of 1 year
measure: The seroprotective titers of the EV71 neutralizing antibody in the 6-35 months old subjects
timeFrame: Through study completion, an average of 1 year
Secondary outcomes:
measure: The incidence of adverse events after the EV71 vaccination in the 6-35 months old subjects
timeFrame: Within 6 months after each dose injection
measure: The seroprotective titers of the CA16, CA6, CA10 neutralizing antibody in the 6-35 months old subjects
timeFrame: Through study completion, an average of 1 year
measure: The seropositive rate of the EV71, CA16, CA6, CA10 neutralizing antibody in the 6-71 months old subjects
timeFrame: During the study period, 2 months after the study beginning
measure: The geometric mean titer (GMT) of the EV71, CA16, CA6, CA10 neutralizing antibody in the 6-71 months old subjects
timeFrame: During the study period, 2 months after the study beginning
measure: The seroconversion rate of the EV71 neutralizing antibody after vaccination in the 6-35 months old subjects
timeFrame: 30 days after two doses
measure: The geometric mean increase (GMI) of the EV71 neutralizing antibody after vaccination in the 6-35 months old subjects
timeFrame: 30 days after two doses
measure: Proportions of various pathogens in the confirmed HFMD cases
timeFrame: Through study completion, an average of 1 year
Other outcomes:
Locations:
city: Jingzhou
country: China
facility: Songzi Center for Disease Control and Prevention
state: Hubei
city: Xiantao
country: China
facility: Xiantao Center for Disease Control and Prevention
state: Hubei
Study officials:
affiliation: Hubei Provincial Center for Disease Control and Prevention
name: Xuhua Guan, Doctor
role: PRINCIPAL_INVESTIGATOR
References: